-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2537 Comparative Effectiveness, Safety, and Costs of Rivaroxaban and Warfarin Treatment Among Morbidly Obese Patients with Venous Thromboembolism

Program: Oral and Poster Abstracts
Session: 332. Antithrombotic Therapy: Poster II
Hematology Disease Topics & Pathways:
Diseases, Bleeding and clotting
Sunday, December 2, 2018, 6:00 PM-8:00 PM
Hall GH (San Diego Convention Center)

Alex C. Spyropoulos, MD1*, Veronica Ashton, MPH2*, Yen-Wen Chen2*, Bingcao Wu2* and Eric D. Peterson3*

1Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Department of Medicine, Anticoagulation and Clinical Thrombosis Services, Northwell Health System, The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY
2Janssen Scientific Affairs, LLC, Titusville, NJ
3Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

Background: Use of direct-acting oral anticoagulants (DOACs) in morbidly obese (BMI >40 kg/m2) patients for venous thromboembolism (VTE) treatment is not fully understood. Current International Society of Thrombosis and Haemostasis guidelines do not recommend DOAC use in morbidly obese patients due to limited clinical data in this patient population.

Objective: Compare risk of recurrent VTE, major bleeding, healthcare resource utilization, and costs between morbidly obese VTE patients initiating rivaroxaban or warfarin treatment.

Methods: This is a retrospective 1:1 propensity score matched cohort study. VTE patients initiating rivaroxaban or warfarin were identified from Truven MarketScan Commercial Claims and Encounters and Medicare Supplemental database (12/1/2011-12/31/2016). An ICD-9/ICD-10 diagnosis code for morbid obesity was required during the 12 months pre- or 3 months post-initiation. Patients were followed ≥3 months. Analyses were conducted during the entire follow-up period regardless of discontinuation as well as on-treatment prior to discontinuation of index treatment. Major bleeding was assessed using the validated claims-based algorithm developed by Cunningham et al. 2011. Conditional logistic regression and generalized linear models were used to compare recurrent VTE and major bleeding risks, all-cause healthcare resource utilization, and per patient per year (PPPY) costs.

Results: Among 5,780 rivaroxaban or warfarin treated patients (2,890 in each matched cohort), mean age was 53 ±13 years; 60% were female; mean follow-up time was 10.0 months and 10.5 months, respectively. Mean time between VTE diagnosis and treatment start was 14 days. Risk of recurrent VTE was similar for both cohorts in the intent-to-treat analysis (OR: 0.99, 95% CI: 0.85-1.14, p=0.844). Major bleeding risk was numerically lower for the rivaroxaban cohort but did not reach statistical significance in the on-treatment analysis (OR: 0.75, 95% CI: 0.47-1.19, p=0.227). Rivaroxaban treated patients utilized fewer all-cause healthcare resources, specifically inpatient hospitalizations (OR: 0.86, 95% CI: 0.77-0.96, p=0.006) and outpatient visits (OR: 0.23, 95% CI: 0.10-0.56, p=0.001) compared to warfarin (Table). Rivaroxaban patients incurred an average $2,829 lower total medical costs PPPY, ($34,824 vs $37,653, p=0.020), mainly driven by hospitalization costs. Total healthcare costs (including pharmacy) showed a numerical $1,531 reduction for rivaroxaban patients, not reaching statistical significance ($43,034 vs. $44,565, p=0.237).

Conclusions: Our study showed that morbidly obese VTE patients treated with rivaroxaban had similar risk of recurrent VTE and major bleeding compared to warfarin. Treatment with rivaroxaban yielded less all-cause healthcare resource utilization (i.e. inpatient hospitalizations and outpatient visits) and reduced total medical costs.

Disclosures: Spyropoulos: Janssen Scientific Affairs, LLC: Consultancy. Ashton: Janssen Scientific Affairs, LLC: Employment. Chen: Janssen Scientific Affairs, LLC: Employment. Wu: Janssen Scientific Affairs, LLC: Employment. Peterson: Janssen Scientific Affairs, LLC: Consultancy.

*signifies non-member of ASH